Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Cholangiocarcinoma | Research

ROR1-AS1 might promote in vivo and in vitro proliferation and invasion of cholangiocarcinoma cells

Authors: Xueliang Li, Zhaowei Sun, Li Wang, Qinlei Wang, Maobing Wang, Jingyun Guo, Haoran Li, MenShou Chen, Guanghua Cao, Yanan Yu, Haochen Zhong, Hao Zou, Kai Ma, Bingyuan Zhang, Guolei Wang, Yujie Feng

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Long non-coding RNAs (lncRNAs) play important roles in many pathophysiological processes, including cancer progression. Namely, lncRNA Receptor-tyrosine-kinase-like orphan receptor-1 antisense 1 (ROR1-AS1) is crucial for cancer occurrence and progression in organs such as the liver or bladder. However, its expression and role in cholangiocarcinoma (CCA) have not been thoroughly explored.
Firstly, we assessed cell viability, proliferation, invasion, and migration using three cell lines (HuCCT-1, QBC399, and RBE) to explore the biological characteristics of ROR1-AS1 in CCA. Secondly, to determine the in vivo effect of ROR1-AS1 on tumor growth, ROR1-AS1 knockdown (KD) HuCCT-1 cells were subcutaneously injected into nude mice to evaluate tumor growth. Finally, we conducted a bioinformatic analysis to confirm the role of ROR1-AS1 in the prognosis and immunity of CCA.
In this study, we found that lncRNA ROR1-AS1 was increased in CCA samples and patients with higher ROR1-AS1 expression had a shorter overall survival period. siRNA-mediated KD of ROR1-AS1 significantly reduced cell proliferation and inhibited the migration of CCA cells. In addition, ROR1-AS1 KD HuCCT-1 cells injected into nude mice grew slower than normal CCA cells.
In summary, our results show that ROR1-AS1 can promote CCA progression and might serve as a new target for diagnosis and treatment of CCA.
Appendix
Available only for authorised users
Literature
1.
Bragazzi MC, Ridola L, Safarikia S, Matteo SD, Costantini D, Nevi L, Cardinale V. New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin. Ann Gastroenterol. 2018;31(1):42–55.PubMed
2.
3.
Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Ahn DH, Aderka D, et al. Overall survival and clinical characteristics of BRCA-Associated Cholangiocarcinoma: a Multicenter Retrospective Study. Oncologist. 2017;22(7):804–10.CrossRefPubMedPubMedCentral
4.
Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215–29.CrossRefPubMed
5.
Balakrishnan A, Goodpaster T, Randolph-Habecker J, Hoffstrom BG, Jalikis FG, Koch LK, Berger C, Kosasih PL, Rajan A, Sommermeyer D, et al. Analysis of ROR1 protein expression in Human Cancer and normal tissues. Clin Cancer Res. 2017;23(12):3061–71.CrossRefPubMed
6.
Masiakowski P, Carroll RD. A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem. 1992;267(36):26181–90.CrossRefPubMed
7.
Hu G, Gupta SK, Troska TP, Nair A, Gupta M. Long non-coding RNA profile in mantle cell lymphoma identifies a functional lncRNA ROR1-AS1 associated with EZH2/PRC2 complex. Oncotarget. 2017;8(46):80223–34.CrossRefPubMedPubMedCentral
8.
Zhang L, Yao HR, Liu SK, Song LL. Long noncoding RNA ROR1–AS1 overexpression predicts poor prognosis and promotes metastasis by activating Wnt/β-catenin/EMT signaling cascade in cervical cancer. Eur Rev Med Pharmacol Sci. 2020;24(6):2928–37.PubMed
9.
Wang FZ, Zhang MQ, Zhang L, Zhang MC. Long non-coding RNA ROR1-AS1 enhances colorectal cancer metastasis by targeting miR-375. Eur Rev Med Pharmacol Sci. 2021;25(4):1764.PubMed
10.
Xu N, Qiao L, Yin L, Li H. Long noncoding RNA ROR1-AS1 enhances lung adenocarcinoma metastasis and induces epithelial-mesenchymal transition by sponging miR-375. J buon. 2019;24(6):2273–9.PubMed
11.
Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–w514.CrossRefPubMedPubMedCentral
12.
Zhang Z, Wang S, Yang F, Meng Z, Liu Y. LncRNA ROR1–AS1 high expression and its prognostic significance in liver cancer. Oncol Rep. 2020;43(1):55–74.PubMed
13.
Liao T, Maierdan SL, Lv C. ROR1-AS1 promotes tumorigenesis of colorectal cancer via targeting Wnt/β-catenin. Eur Rev Med Pharmacol Sci. 2020;24(14):7561.PubMed
14.
Zhang Z, Zhou Y, Hu K, Wang D, Wang Z, Huang Y. Perineural invasion as a prognostic factor for intrahepatic cholangiocarcinoma after curative resection and a potential indication for postoperative chemotherapy: a retrospective cohort study. BMC Cancer. 2020;20(1):270.CrossRefPubMedPubMedCentral
15.
Meng XL, Lu JC, Zeng HY, Chen Z, Guo XJ, Gao C, Pei YZ, Hu SY, Ye M, Sun QM, et al. The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion. Hepatol Int. 2023;17(1):63–76.CrossRefPubMed
16.
Wang SY, Jiang N, Zeng JP, Yu SQ, Xiao Y, Jin S. Characteristic of Perineural Invasion in Hilar Cholangiocarcinoma based on whole-mount histologic large sections of liver. Front Oncol. 2022;12:855615.CrossRefPubMedPubMedCentral
17.
Li F, Gu F, Li Q, Zhai C, Gong R, Zhu X. ROR1-AS1 knockdown inhibits growth and invasion and promotes apoptosis in NSCLC cells by suppression of the PI3K/Akt/mTOR pathway. J Biochem Mol Toxicol. 2021;35(5):e22726.CrossRefPubMed
18.
Chen Q, Fu L. Upregulation of long non-coding RNA ROR1-AS1 promotes cell growth and migration in bladder cancer by regulation of miR-504. PLoS ONE. 2020;15(1):e0227568.CrossRefPubMedPubMedCentral
19.
Wang S, Chen W, Yu H, Song Z, Li Q, Shen X, Wu Y, Zhu L, Ma Q, Xing D. lncRNA ROR promotes gastric Cancer Drug Resistance. Cancer Control. 2020;27(1):1073274820904694.CrossRefPubMedPubMedCentral
20.
Li X, Zuo C, Wu M, Zhang Z. Linc-ROR promotes arsenite-transformed keratinocyte proliferation by inhibiting P53 activity. Metallomics. 2020;12(6):963–73.CrossRefPubMed
21.
Wallstabe L, Göttlich C, Nelke LC, Kühnemundt J, Schwarz T, Nerreter T, Einsele H, Walles H, Dandekar G, Nietzer SL et al. ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI Insight 2019, 4(18).
22.
Aponte-López A, Muñoz-Cruz S. Mast cells in the Tumor Microenvironment. Adv Exp Med Biol. 2020;1273:159–73.CrossRefPubMed
23.
24.
Kamrani A, Mehdizadeh A, Ahmadi M, Aghebati-Maleki L, Yousefi M. Therapeutic approaches for targeting receptor tyrosine kinase like orphan receptor-1 in cancer cells. Expert Opin Ther Targets. 2019;23(5):447–56.CrossRefPubMed
25.
Hojjat-Farsangi M, Moshfegh A, Daneshmanesh AH, Khan AS, Mikaelsson E, Osterborg A, Mellstedt H. The receptor tyrosine kinase ROR1–an oncofetal antigen for targeted cancer therapy. Semin Cancer Biol. 2014;29:21–31.CrossRefPubMed
26.
Shabani M, Naseri J, Shokri F. Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy. Expert Opin Ther Targets. 2015;19(7):941–55.CrossRefPubMed
Metadata
Title
ROR1-AS1 might promote in vivo and in vitro proliferation and invasion of cholangiocarcinoma cells
Authors
Xueliang Li
Zhaowei Sun
Li Wang
Qinlei Wang
Maobing Wang
Jingyun Guo
Haoran Li
MenShou Chen
Guanghua Cao
Yanan Yu
Haochen Zhong
Hao Zou
Kai Ma
Bingyuan Zhang
Guolei Wang
Yujie Feng
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11412-1

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Two-institution results of Stereotactic Body Radiation Therapy (SBRT) for treating adrenal gland metastases from liver cancer

Research

Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis

Research

Interaction analysis of high-risk pathological features on adjuvant chemotherapy survival benefit in stage II colon cancer patients: a multi-center, retrospective study

Research

Analysis of mRNA-miRNA interaction network reveals the role of CAFs-derived exosomes in the immune regulation of oral squamous cell carcinoma

Research

Pan-cancer analysis of whole-genome doubling and its association with patient prognosis

Research

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits